Helen Michael

  • 2599 Citations
  • 29 h-Index
1979 …2017
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Helen Michael is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 21 Similar Profiles
Germ Cell and Embryonal Neoplasms Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Adenocarcinoma Medicine & Life Sciences
Ovary Medicine & Life Sciences
Carcinoma Medicine & Life Sciences
Dysgerminoma Medicine & Life Sciences
Endodermal Sinus Tumor Medicine & Life Sciences
Ovarian Neoplasms Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Publications 1979 2017

  • 2599 Citations
  • 29 h-Index
  • 47 Article
  • 5 Chapter
  • 1 Comment/debate
  • 1 Review article
46 Citations (Scopus)

Bevacizumab for advanced cervical cancer: Final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)

Tewari, K. S., Sill, M. W., Penson, R. T., Huang, H., Ramondetta, L. M., Landrum, L. M., Oaknin, A., Reid, T. J., Leitao, M. M., Michael, H., DiSaia, P. J., Copeland, L. J., Creasman, W. T., Stehman, F., Brady, M. F., Burger, R. A., Thigpen, J. T., Birrer, M. J., Waggoner, S. E., Moore, D. H. & 3 others, Look, K. Y., Koh, W. J. & Monk, B. J., 2017, (Accepted/In press) In : The Lancet.

Research output: Contribution to journalArticle

Uterine Cervical Neoplasms
Drug Therapy
Survival
Fistula
Paclitaxel

Weekly Versus Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer

Chan, J. K., Brady, M. F., Penson, R. T., Huang, H., Birrer, M. J., Walker, J. L., Disilvestro, P. A., Rubin, S. C., Martin, L. P., Davidson, S. A., Huh, W. K., O'Malley, D. M., Boente, M. P., Michael, H. & Monk, B. J., Jun 1 2016, In : Obstetrical and Gynecological Survey. 71, 6, p. 344-345 2 p.

Research output: Contribution to journalComment/debate

Carboplatin
Paclitaxel
Ovarian Neoplasms
104 Citations (Scopus)

Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer

Chan, J. K., Brady, M. F., Penson, R. T., Huang, H., Birrer, M. J., Walker, J. L., DiSilvestro, P. A., Rubin, S. C., Martin, L. P., Davidson, S. A., Huh, W. K., O'Malley, D. M., Boente, M. P., Michael, H. & Monk, B. J., Feb 25 2016, In : New England Journal of Medicine. 374, 8, p. 738-748 11 p.

Research output: Contribution to journalArticle

Carboplatin
Paclitaxel
Ovarian Neoplasms
Disease-Free Survival
Confidence Intervals
59 Citations (Scopus)

Bevacizumab for advanced cervical cancer: Patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240)

Penson, R. T., Huang, H. Q., Wenzel, L. B., Monk, B. J., Stockman, S., Long, H. J., Ramondetta, L. M., Landrum, L. M., Oaknin, A., Reid, T. J. A., Leitao, M. M., Method, M., Michael, H. & Tewari, K. S., Mar 1 2015, In : The Lancet Oncology. 16, 3, p. 301-311 11 p.

Research output: Contribution to journalArticle

Uterine Cervical Neoplasms
Quality of Life
Therapeutics
Drug Therapy
Patient Reported Outcome Measures
2 Citations (Scopus)
Neuroendocrine Carcinoma
Loss of Heterozygosity
X Chromosome Inactivation
Molecular Biology
Adenocarcinoma